R
Robert Kridel
Researcher at Princess Margaret Cancer Centre
Publications - 96
Citations - 4888
Robert Kridel is an academic researcher from Princess Margaret Cancer Centre. The author has contributed to research in topics: Follicular lymphoma & Diffuse large B-cell lymphoma. The author has an hindex of 29, co-authored 78 publications receiving 3773 citations. Previous affiliations of Robert Kridel include BC Cancer Research Centre & Ludwig Institute for Cancer Research.
Papers
More filters
Journal ArticleDOI
Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry
Alessandro Pastore,Vindi Jurinovic,Robert Kridel,Eva Hoster,Annette M. Staiger,Annette M. Staiger,Monika Szczepanowski,Christiane Pott,Nadja Kopp,Mark A. Murakami,Heike Horn,Heike Horn,Ellen Leich,Alden A. Moccia,Anja Mottok,Ashwini Sunkavalli,Paul Van Hummelen,Matthew D. Ducar,Daisuke Ennishi,Hennady P. Shulha,Christoffer Hother,Joseph M. Connors,Laurie H. Sehn,Martin Dreyling,Donna Neuberg,Peter Möller,Alfred C. Feller,Martin L. Hansmann,Harald Stein,Andreas Rosenwald,German Ott,Wolfram Klapper,Michael Unterhalt,Wolfgang Hiddemann,Randy D. Gascoyne,David M. Weinstock,Oliver Weigert +36 more
TL;DR: This work aimed to improve risk stratification of patients receiving first-line immunochemotherapy by integrating gene mutations into a prognostic model by establishing a clinicogenetic risk model that included the Follicular Lymphoma International Prognostic Index (FLIPI) and Eastern Cooperative Oncology Group (ECOG) performance status.
Journal ArticleDOI
Whole transcriptome sequencing reveals recurrent NOTCH1 mutations in mantle cell lymphoma
Robert Kridel,Robert Kridel,Barbara Meissner,Sanja Rogic,Merrill Boyle,Adele Telenius,Bruce Woolcock,Jay Gunawardana,Jay Gunawardana,Christopher R Jenkins,Chris Cochrane,Susana Ben-Neriah,King Tan,Ryan D. Morin,Stephen Opat,Laurie H. Sehn,Joseph M. Connors,Marco A. Marra,Andrew P. Weng,Christian Steidl,Christian Steidl,Randy D. Gascoyne,Randy D. Gascoyne +22 more
TL;DR: Recurrent NOTCH1 mutations are identified that provide the preclinical rationale for therapeutic inhibition of the NOTCH pathway in a subset of patients with MCL and are shown to reduce proliferation and induced apoptosis in 2 MCL cell lines.
Journal ArticleDOI
Prognostic Significance of Diffuse Large B-Cell Lymphoma Cell of Origin Determined by Digital Gene Expression in Formalin-Fixed Paraffin-Embedded Tissue Biopsies
David W. Scott,Anja Mottok,Daisuke Ennishi,George E. Wright,Pedro Farinha,Susana Ben-Neriah,Robert Kridel,Garrett S. Barry,Christoffer Hother,Pau Abrisqueta,Merrill Boyle,Barbara Meissner,Adele Telenius,Kerry J. Savage,Laurie H. Sehn,Graham W. Slack,Christian Steidl,Louis M. Staudt,Joseph M. Connors,Lisa M. Rimsza,Randy D. Gascoyne +20 more
TL;DR: Assignment of DLBCL COO by the Lymph2Cx assay using FFPET biopsies identifies patient groups with significantly different outcomes after R-CHOP, independent of IPI score and MYC/BCL2 dual expression.
Journal ArticleDOI
Pharmacological and genomic profiling identifies NF-κB–targeted treatment strategies for mantle cell lymphoma
Rami Rahal,Mareike Frick,Rodrigo Romero,Joshua M. Korn,Robert Kridel,Fong Chun Chan,Barbara Meissner,Hyo-eun C. Bhang,Dave Ruddy,Audrey Kauffmann,Ali Farsidjani,Adnan Derti,Daniel P. Rakiec,Tara L. Naylor,Estelle Pfister,Steve Kovats,Sunkyu Kim,Kerstin Dietze,Bernd Dörken,Christian Steidl,Alexandar Tzankov,Michael Hummel,John Monahan,Michael Morrissey,Christine Fritsch,William R. Sellers,Vesselina G. Cooke,Randy D. Gascoyne,Georg Lenz,Frank Stegmeier +29 more
TL;DR: It is revealed that NIK is a new therapeutic target for MCL treatment, particularly for lymphomas that are refractory to BCR pathway inhibitors and provide critical insights into patient stratification strategies for NF-κB pathway–targeted agents.
Journal ArticleDOI
Pathogenesis of follicular lymphoma
TL;DR: Crosstalk between neoplastic B cells and non-neoplastic immune and stromal cells in the microenvironment plays an important role in sustaining tumor cell growth, cultivating immune privilege, and promoting transformation.